FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285586350> ?p ?o ?g. }

• W4285586350 endingPage "100536" @default.
• W4285586350 startingPage "100536" @default.
• W4285586350 abstract "•Preclinical data indicate that PARPis exhibit immune modulating properties.•The combination of PARPi with ICIs displays significant synergistic activity in preclinical models.•Phase I and II clinical trials showed encouraging results for this combination, especially in platinum-resistant OC.•Four ongoing phase III trials exploring the combination in first-line setting will delineate the role of immunotherapy in OC. Immune checkpoint inhibitors (ICIs) have completely reshaped the treatment of many malignancies, with remarkable improvements in survival outcomes. In ovarian cancer (OC), however, this emerging class of drugs has not yet found a favorable use due to results from phase I and II studies, which have not suggested a substantial antitumoral activity of these agents when administered as monotherapy. Robust preclinical data seem to suggest that the combination ICIs with poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) may result in a synergistic activity; furthermore, data from phase II clinical studies, evaluating this combination, have shown encouraging outcomes especially for those OC patients not suitable for platinum retreatment. While waiting for ongoing phase III clinical trial results, which will clarify the role of ICIs in combination with PARPis in the newly diagnosed OC, this review aims to summarize the preclinical data and clinical evidence available to date. Immune checkpoint inhibitors (ICIs) have completely reshaped the treatment of many malignancies, with remarkable improvements in survival outcomes. In ovarian cancer (OC), however, this emerging class of drugs has not yet found a favorable use due to results from phase I and II studies, which have not suggested a substantial antitumoral activity of these agents when administered as monotherapy. Robust preclinical data seem to suggest that the combination ICIs with poly(ADP-ribose) polymerase (PARP) inhibitors (PARPis) may result in a synergistic activity; furthermore, data from phase II clinical studies, evaluating this combination, have shown encouraging outcomes especially for those OC patients not suitable for platinum retreatment. While waiting for ongoing phase III clinical trial results, which will clarify the role of ICIs in combination with PARPis in the newly diagnosed OC, this review aims to summarize the preclinical data and clinical evidence available to date." @default.
• W4285586350 created "2022-07-16" @default.
• W4285586350 creator A5000969455 @default.
• W4285586350 creator A5006723870 @default.
• W4285586350 creator A5009634950 @default.
• W4285586350 creator A5014493498 @default.
• W4285586350 creator A5014673156 @default.
• W4285586350 creator A5015546322 @default.
• W4285586350 creator A5016608376 @default.
• W4285586350 creator A5026048739 @default.
• W4285586350 creator A5040656664 @default.
• W4285586350 creator A5042216932 @default.
• W4285586350 creator A5050846630 @default.
• W4285586350 creator A5061939825 @default.
• W4285586350 creator A5083899655 @default.
• W4285586350 date "2022-08-01" @default.
• W4285586350 modified "2023-09-26" @default.
• W4285586350 title "Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon?" @default.
• W4285586350 cites W1484451637 @default.
• W4285586350 cites W1891447727 @default.
• W4285586350 cites W1973268287 @default.
• W4285586350 cites W1995733047 @default.
• W4285586350 cites W2011458181 @default.
• W4285586350 cites W2016164706 @default.
• W4285586350 cites W2062886301 @default.
• W4285586350 cites W2063384194 @default.
• W4285586350 cites W2073580835 @default.
• W4285586350 cites W2106910596 @default.
• W4285586350 cites W2111667552 @default.
• W4285586350 cites W2117964602 @default.
• W4285586350 cites W2127107746 @default.
• W4285586350 cites W2128746885 @default.
• W4285586350 cites W2177072498 @default.
• W4285586350 cites W2291298003 @default.
• W4285586350 cites W2522054472 @default.
• W4285586350 cites W2586604009 @default.
• W4285586350 cites W2587333476 @default.
• W4285586350 cites W2590978913 @default.
• W4285586350 cites W2622499649 @default.
• W4285586350 cites W2749055363 @default.
• W4285586350 cites W2767551096 @default.
• W4285586350 cites W2770647635 @default.
• W4285586350 cites W2802480234 @default.
• W4285586350 cites W2890261294 @default.
• W4285586350 cites W2900109386 @default.
• W4285586350 cites W2903353464 @default.
• W4285586350 cites W2903718866 @default.
• W4285586350 cites W2914850591 @default.
• W4285586350 cites W2939570668 @default.
• W4285586350 cites W2942052760 @default.
• W4285586350 cites W2947257322 @default.
• W4285586350 cites W2947993621 @default.
• W4285586350 cites W2952108487 @default.
• W4285586350 cites W2963384555 @default.
• W4285586350 cites W2975141952 @default.
• W4285586350 cites W2981585441 @default.
• W4285586350 cites W2994977341 @default.
• W4285586350 cites W3001817448 @default.
• W4285586350 cites W3005396695 @default.
• W4285586350 cites W3011278583 @default.
• W4285586350 cites W3016085372 @default.
• W4285586350 cites W3028523516 @default.
• W4285586350 cites W3028739923 @default.
• W4285586350 cites W3032852436 @default.
• W4285586350 cites W3034529377 @default.
• W4285586350 cites W3038035987 @default.
• W4285586350 cites W3040762998 @default.
• W4285586350 cites W3047415922 @default.
• W4285586350 cites W3112763789 @default.
• W4285586350 cites W3124398175 @default.
• W4285586350 cites W3153473864 @default.
• W4285586350 cites W3169849224 @default.
• W4285586350 cites W3175481001 @default.
• W4285586350 cites W3188131079 @default.
• W4285586350 cites W3196142179 @default.
• W4285586350 cites W3199207936 @default.
• W4285586350 cites W3202313996 @default.
• W4285586350 cites W3203779476 @default.
• W4285586350 cites W3204289211 @default.
• W4285586350 cites W3204360130 @default.
• W4285586350 cites W3204509441 @default.
• W4285586350 cites W3206329003 @default.
• W4285586350 cites W4200210492 @default.
• W4285586350 cites W4220751663 @default.
• W4285586350 cites W4226480857 @default.
• W4285586350 doi "https://doi.org/10.1016/j.esmoop.2022.100536" @default.
• W4285586350 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35849879" @default.
• W4285586350 hasPublicationYear "2022" @default.
• W4285586350 type Work @default.
• W4285586350 citedByCount "9" @default.
• W4285586350 countsByYear W42855863502022 @default.
• W4285586350 countsByYear W42855863502023 @default.
• W4285586350 crossrefType "journal-article" @default.
• W4285586350 hasAuthorship W4285586350A5000969455 @default.
• W4285586350 hasAuthorship W4285586350A5006723870 @default.
• W4285586350 hasAuthorship W4285586350A5009634950 @default.
• W4285586350 hasAuthorship W4285586350A5014493498 @default.
• W4285586350 hasAuthorship W4285586350A5014673156 @default.

• next